Massive ovarian haemorrhage complicating oral anticoagulation in the Antiphospholipid Syndrome: A report of three cases

Lupus

Volumn 8, Issue 6, 1999, Pages 482-485

  Crétel, Elodie ^a   Cacoub, Patrice ^a   Huong, Du Le Thi ^a   Gompel, Anne ^b   Amoura, Zahir ^a   Piette, Jean Charles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔTEL DIEU   (France)

Author keywords

Antiphospholipid syndrome; Oral anticoagulation; Ovarian haemorrhage

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CHLORMADINONE; FLUINDIONE; GESTAGEN; GONADOTROPIN ANTAGONIST; HEPARIN; HYDROCORTISONE; WARFARIN;

ABDOMINAL PAIN; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLEEDING; CASE REPORT; CONTRACEPTION; FEMALE; HEMOSTASIS; HUMAN; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; ORAL DRUG ADMINISTRATION; OVARY CYST; OVARY DISEASE; OVULATION INHIBITION; PRIORITY JOURNAL;

EID: 0345425818     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339900800614     Document Type: Article

References (30)

1. Rosove MH, Brewer PM. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-308.
2. Derksen RHWM, DeGroot PG, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689-692.
3. Khamashta MA, Cuadrado MJ, Mujic F et al, The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
4. Krnic-Barrie S, O'Connor CR, Looney SW et al. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101-2108.
5. Piette JC, Cacoub P. Antiphospholipid syndrome in the elderly: caution. Circulation 1998; 97: 2195-2196.
6. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114: 511S-523S.
7. Boffa MC, Piette JC. Questions-answers about antiphospholipid-protein antibodies and the 'antiphospholipid antibody syndrome'. Ann Med Interne 1996; 147(Suppl 1): 54-56.
8. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding; clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-328.
9. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 1993; 118: 511-520.
10. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-428.
11. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409-416.
12. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
13. Al-Sayegh FA, Ensworth S, Huang S et al. Hemorrhagic complications of longterm anticoagulant therapy in 7 patients with systemic lupus erythematosus and antiphospholipid syndrome. J Rheumatol 1997; 24: 1716-1718.
14. Sopher IM, Ming SC. Fatal corpus luteum hemorrhage during anticoagulant therapy. Obstet Gynecol 1971; 37: 695-697.
15. Matseoane S, Batts JA Jr, Mandeville EO. Ovarian hemorrhage complicating warfarin sodium anticoagulant therapy. Am J Obstet Gynecol 1976; 124: 766-767.
16. Semchyshyn S, Zuspan FP. Ovarian hemorrhage due to anticoagulants. Am J Obstet Gynecol 1978; 131: 837-844.
17. Peters WA III, Thiagarajah S, Thornton WN Jr. Ovarian hemorrhage in patients receiving anticoagulant therapy. J Reprod Med 1979; 22: 82-86.
18. Hallat JG, Steele CH, Snyder M. Ruptured corpus luteum with hemoperitoneum: a study of 173 surgical cases. Am J Obstet Gynecol 1984; 149: 5-9.
19. Hill JA, Kassam SH. Ovarian hemorrhage in ovulating women receiving anticoagulant therapy. A report of two cases. J Reprod Med 1984; 29: 205-208.
20. Asherson RA. Adrenal, hepatic, and other intraabdominal manifestations in the antiphospholipid syndrome. In: The Antiphospholipid Syndrome, Asherson RA, Cervera R, Piette JC, Shoenfeld Y (ed). Boca Raton: CRC Press 1996, 183-193.
21. Hibbard LT. Corpus luteum surgery. Am J Obstet Gynecol 1979; 135: 666-670.
22. Ruffatti A, Aversa S, Del Ross T et al. Antiphospholipid antibody syndrome associated with ovarian cancer. A new paraneoplastic syndrome? J Rheumatol 1994; 21: 2162-2163.
23. Piette JC, Wechsler B. Other aspects of the management of the antiphospholipid syndrome. In: The Antiphospholipid Syndrome, Asherson RA, Cervera R, Piette JC, Shoenfeld Y (Ed). Boca Raton: CRC Press. 1996, 309-314.
24. Petri M, Clinical and management aspects of the antiphospholipid syndrome. In: Dubois ' Lupus Erythematosus, 5th edition, Wallace DJ, Hahn BH (ed). Baltimore: Williams & Wilkins, 1997, 1067-1096.
25. Chabbert-Buffet N, Blétry O, Clauvel JP et al. Pregnane progestin is a safe contraception in systemic lupus erythematosus (abstract). Lupus 1998; 7 (Suppl 1): 111.
26. Boumpas DT, Austin HA III, Vaughan EM et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-369.
27. Gompel A, Blétry O. Contraception et grossesse au cours du lupus érythémateux systémique. Rev Prat 1990; 40: 1946-1951.
28. Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985; 92: 1003-1009.
29. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177-185.
30. Praprotnik S, Prezely J. Ovaries in systemic lupus erythematosus. Lupus 1995; 4: 418.